학술논문
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Document Type
Article
Author
Madhi, Shabir A ; Koen, Anthonet L; Izu, Alane; Fairlie, Lee; Cutland, Clare L; Baillie, Vicky; Padayachee, Sherman D; Dheda, Keertan; Barnabas, Shaun L; Bhorat, Qasim Ebrahim; Briner, Carmen; Aley, Parvinder K; Bhikha, Sutika; Hermanus, Tandile; Horne, Elizea; Jose, Aylin; Kgagudi, Prudence; Lambe, Teresa; Masenya, Masebole; Masilela, Mduduzi; Mkhize, Nonhlanhla; Moultrie, Andrew; Mukendi, Christian K; Moyo-Gwete, Thandeka; Nana, Amit J; Nzimande, Ayanda; Patel, Faeezah; Rhead, Sarah; Taoushanis, Carol; Thombrayil, Asha; van Eck, Samuel; Voysey, Merryn; Villafana, Tonya L; Vekemans, Johan; Gilbert, Sarah C; Pollard, Andrew J; Moore, Penny L ; Kwatra, Gaurav
Source
In The Lancet HIV September 2021 8(9):e568-e580
Subject
Language
ISSN
2352-3018